BX 002
Alternative Names: BX-002Latest Information Update: 28 Dec 2023
At a glance
- Originator BiomX
- Class Anti-inflammatories; Antibacterials; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in USA (PO)
- 17 Dec 2021 Pharmacokinetics and adverse events data from a phase I pharmacokinetic trial in Inflammatory bowel disease presented at 29th United European Gastroenterology Week
- 12 Nov 2021 Pharmacokinetics and adverse events data from a phase I pharmacokinetic trial in Inflammatory bowel disease presented at 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD- 2021)